Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

Akeso, Inc. (9926.HK)

Compare
82.200
+8.050
+(10.86%)
At close: 4:08:17 PM GMT+8
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 9926.HK

Recent News: 9926.HK

View More
High Growth Tech Stocks In Asia To Watch March 2025

High Growth Tech Stocks In Asia To Watch March 2025
Simply Wall St. 12 days ago
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies

Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
PR Newswire 12 days ago
Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025

Akeso to Host 2024 Full-Year Financial Results and Corporate Update Call on Monday, March 31, 2025
PR Newswire 14 days ago
Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting

Akeso's Cadonilimab Combined with Concurrent Chemoradiotherapy Demonstrates Promising Efficacy in Locally Advanced Cervical Cancer: Data Published at the 2025 SGO Annual Meeting
PR Newswire 21 days ago
Asian Growth Companies Insiders Are Eager To Own

Asian Growth Companies Insiders Are Eager To Own
Simply Wall St. 22 days ago
AAC Technologies Holdings And 2 Other Asian Stocks Estimated To Be Trading Below Their Intrinsic Values

AAC Technologies Holdings And 2 Other Asian Stocks Estimated To Be Trading Below Their Intrinsic Values
Simply Wall St. 22 days ago
Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer

Akeso's Penpulimab Receives NMPA Approval for First-Line Treatment of Nasopharyngeal Cancer
PR Newswire 25 days ago
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet

Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
PR Newswire last month
Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma
PR Newswire last month
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy

Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for "IO 2.0 + ADC" Strategy
PR Newswire last month
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine

A little-known Chinese company made a drug that beat the world’s biggest-selling medicine
CNN Business last month
View More

Related Tickers

1801.HK INNOVENT BIO
47.750
+9.27%
 
6160.HK BeiGene, Ltd.
136.700
+4.35%
 
2142.HK HBM Holdings Limited
7.150
+10.51%
 
2269.HK WuXi Biologics (Cayman) Inc.
19.940
+3.75%
 
9688.HK Zai Lab Limited
22.200
+1.83%
 
1541.HK IMMUNEONCO-B
5.220
+5.45%
 
6990.HK Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
302.000
+7.55%
 
2616.HK CStone Pharmaceuticals
2.390
+3.46%
 
1530.HK 3SBIO
12.400
+5.26%
 
9966.HK Alphamab Oncology
6.370
+7.42%